Cargando…
Pragmatic dose-escalation methods incorporating relative dose intensity assessment for molecularly targeted agents in phase I trials
The recommended phase 2 doses of molecularly targeted agents, determined by using an ordinal dose-finding method that only uses toxicity data at first cycle, may not be optimal. Some researchers have proposed the use of relative dose intensity that can account for late-onset, cumulative, and low-gra...
Autores principales: | Hirakawa, Akihiro, Tanaka, Yuichi, Kaneko, Shuhei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883296/ https://www.ncbi.nlm.nih.gov/pubmed/31799475 http://dx.doi.org/10.1016/j.conctc.2019.100489 |
Ejemplares similares
-
Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents
por: Le Tourneau, Christophe, et al.
Publicado: (2012) -
Modern dose-finding designs for cancer phase I trials: drug combinations and molecularly targeted agents
por: Hirakawa, Akihiro, et al.
Publicado: (2018) -
Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose‐finding trials
por: Hirakawa, Akihiro, et al.
Publicado: (2017) -
Dose Escalation Methods in Phase I Cancer Clinical Trials
por: Le Tourneau, Christophe, et al.
Publicado: (2009) -
Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
por: Wheeler, Graham M.
Publicado: (2016)